^
    Back
    Association details:
    Biomarker:BRCA1 mutation
    Cancer:Solid Tumor
    Drug:ART558 (POLQ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Nat Commun
    Title:

    Pol? inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance

    Published date:
    06/17/2021
    Excerpt:
    In addition, ART558 elicits DNA damage and synthetic lethality in BRCA1- or BRCA2-mutant tumour cells...
    DOI:
    10.1038/s41467-021-23463-8